Related Experiment Video
Updated: Aug 6, 2026

The α-test: Rapid Cell-free CD4 Enumeration Using Whole Saliva
Published on: May 16, 2012
Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART)
Alan L Lin1, Dorthea A Johnson, Carol Ann Sims
1Department of Dental Diagnostic Science, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Objective:
This study was undertaken to determine if HAART alters salivary oral host defense in HIV(+) men.
Study Design:
Whole, parotid, and submandibular/sublingual saliva was collected from 39 healthy men and 147 HIV(+) patients with mild to moderate immune dysfunction (69 treated with HAART [HAART(+)]; 78 not treated [HAART(-)]). Salivary flow rates, anticandidal activities, electrolytes, and antimicrobial/antifungal proteins were determined.
Results:
While CD4(+) cell counts were not different between the HIV(+) groups, the median viral load for HAART(-) was 15 times greater than HAART(+). For both HAART groups, salivary yeast carriage rates and concentration were comparable and both showed similar reductions in salivary flow rates. Salivary anticandidal activities were not altered. Saliva composition of both HIV(+) groups was different from control, but only uric acid in parotid saliva of HAART(+) differed from HAART(-).
Conclusions:
HAART does not adversely affect inherent salivary oral host defense in HIV(+) patients with mild to moderate immune dysfunction.
Related Concept Videos
Retrovirus Life Cycles
Salivary Glands and Saliva
Sexually Transmitted Infections
Inhibitors of Virion Maturation and Assembly
Herpes
Size and Structure of Viral Genomes

